β1-Adrenoceptor blockade mitigates excessive norepinephrine release into cardiac interstitium in mitral regurgitation in dog

American Journal of Physiology - Heart and Circulatory Physiology

Volumn 291, Issue 1, 2006, Pages

  Hankes, Gerald H ^a   Ardell, Jeffrey L ^b   Tallaj, José ^c   Wei, Chih Chang ^c   Aban, Inmaculada ^d   Holland, Merrilee ^a   Rynders, Patricia ^a   Dillon, Ray ^a   Cardinal, Rene ^e   Hoover, Donald B ^b   Armour, J Andrew ^e   Husain, Ahsan ^c   Dell'Italia, Louis J ^c,d  

^a AUBURN UNIVERSITY   (United States)

^b EAST TENNESSEE STATE UNIVERSITY   (United States)

^c UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

^d UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

^e UNIVERSITÉ DE MONTRÉAL   (Canada)

Author keywords

Epinephrine; Interstitial fluid

Indexed keywords

BETA 1 ADRENERGIC RECEPTOR BLOCKING AGENT; METOPROLOL SUCCINATE; NORADRENALIN; BETA 1 ADRENERGIC RECEPTOR; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; DRUG DERIVATIVE; METOPROLOL;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CONTROLLED STUDY; DOG; DRUG INHIBITION; DRUG MECHANISM; DRUG RELEASE; HEART LEFT VENTRICLE PRESSURE; HEART MUSCLE CELL; HEART RATE; IN VIVO STUDY; MICRODIALYSIS; MITRAL VALVE REGURGITATION; NONHUMAN; NORADRENALIN RELEASE; PRIORITY JOURNAL; STELLATE GANGLION; ANIMAL; DRUG ANTAGONISM; DRUG EFFECT; EXTRACELLULAR FLUID; FEMALE; HEART MUSCLE; MALE; METABOLISM; TREATMENT OUTCOME;

ADRENERGIC BETA-ANTAGONISTS; ANIMALS; DOGS; EXTRACELLULAR FLUID; FEMALE; MALE; METOPROLOL; MITRAL VALVE INSUFFICIENCY; MYOCARDIUM; NOREPINEPHRINE; RECEPTORS, ADRENERGIC, BETA-1; TREATMENT OUTCOME;

EID: 33745726654     PISSN: 03636135     EISSN: 15221539     Source Type: Journal    
DOI: 10.1152/ajpheart.00951.2005     Document Type: Article

References (25)

1. Borer JS and Bonow RO. Contemporary approach to aortic and mitral regurgitation. Circulation 108: 2432-2438, 2003.
2. Brink M, de Gasparo M, Rogg H, Whitebread S, and Bullock G. Localization of angiotensin II receptor subtypes in the rabbit heart. J Mol Cell Cardiol 27: 459-470, 1995.
3. Cardinal R, Nadeau R, Laurent C, Boudreau G, and Armour JA. Reduced capacity of cardiac efferent sympathetic neurons to release noradrenaline and modify cardiac function in tachycardia-induced heart failure. Can J Physiol Pharmacol 74: 1070-1078, 1996.
4. Dell'Italia LJ, Balcells E, Meng QC, Su X, Schultz D, Bishop SP, Machida N, Straeter-Knowlen I, Hankes GH, Dillon R, Cartee RE, and Oparil S. Volume overload cardiac hypertrophy is unaffected by ACE inhibitor treatment in the dog. Am J Physiol Heart Circ Physiol 273: H961-H970, 1997.
5. Dong E, Yatani A, Mohan A, and Liang CS. Myocardial β-adrenoceptor down-regulation by norepinephrine is linked to reduced norepinephrine uptake activity. Eur J Pharmacol 384: 17-24, 1999.
6. Farrell DM, Wei CC, Tallaj J, Ardell JL, Hageman GR, Armour JA, Hageman GR, Bradley WE, and Dell'Italia LJ. Angiotensin II modulates catecholamine release into interstitial fluid of canine ventricle in vivo. Am J Physiol Heart Circ Physiol 281: H813-H822, 2001.
7. Himura Y, Felten SY, Kashiki M, Lewandowski TJ, Kelehanty JM, and Liang CS. Cardiac noradrenergic nerve terminal abnormalities in dogs with experimental congestive heart failure. Circulation 88: 1299-1309, 1993.
8. Kawai H, Mohan A, Hagen J, Dong E, Armstrong J, Stevens SY, and Liang CS. Alterations in cardiac adrenergic terminal function and β-adrenoceptor density in pacing-induced heart failure. Am J Physiol Heart Circ Physiol 278: H1708-H1716, 2000.
9. Lohse M, Engelhardt S, and Eschenhagen T. What is the role of β-adrenergic signaling in heart failure? Circ Res 93: 896-906, 2003.
10. Mao W, Iwai C, Qin F, and Liang CS. Norepinephrine induces endoplasmic reticulum stress and downregulation of norepinephrine transporter density in PC12 cells via oxidative stress. Am J Physiol Heart Circ Physiol 288: H2381-H2389, 2005.
11. Mann DL, Kent RL, Parsons B, and Cooper IVG. Adrenergic effects on the biology of the adult mammalian cardiocyte. Circulation 85: 790-804, 1992.
12. Mehta RH, Supiano MA, Oral H, Grossman PM, Montgomery DS, Smith MJ, and Starling MR. Compared with control subjects, the systemic sympathetic nervous system is activated in patients with mitral regurgitation. Am Heart J 145: 1078-1085, 2003.
13. Mehta RH, Supiano MA, Oral Grossman PM, Petrusha JA, Montgomery DG, Briesmiester KA, Smith MJ, and Starling MR. Relation of systemic sympathetic nervous system activation to echocardiographic left ventricular size and performance and its implications in patients with mitral regurgitation. Am J Cardiol 86: 1193-1197, 2000.
14. Muntz KH. Autoradiographic characterization of β-adrenergic receptor subtypes in the canine conduction system. Circ Res 71: 51-57, 1992.
15. Nagatsu M, Zile MR, Tsutsui H, Schmid PG, DeFreyte G, Cooper 4th G, and Carabello BA. Native β-adrenergic support for left ventricular dysfunction in experimental mitral regurgitation normalizes indexes of pump and contractile function. Circulation 89: 818-826, 1994.
16. Nemoto S, Hamawaki M, DeFreitas G, and Carabello BA. Differential effects of the angiotensin-converting enzyme inhibitor lisinopril versus the beta-adrenergic receptor blocker atenolol on hemodynamics and left ventricular contractile function in experimental mitral regurgitation. J Am Coll Cardiol 40: 149-154, 2002.
17. Perry GJ, Wei CC, Hankes GH, Dillon SR, Rynders P, Mukherjee R, Spinale FG, and Dell'Italia LJ. Angiotensin II receptor blockade does not improve left ventricular function and remodeling in subacute mitral regurgitation in the dog. J Am Coll Cardiol 39: 1374-1379, 2002.
18. Siwik DA and Colucci WS. Regulation of matrix metalloproteinases by cytokines and reactive oxygen/nitrogen species in the myocardium. Heart Fail Rev 9: 43-51, 2004.
19. Smith C and Teitler M. Beta-blocker selectivity at cloned human beta1-and beta2-adrenergic receptors. Cardiovasc Drugs Ther 13: 123-126, 1999.
20. Smith FM, McGuirt AS, Hoover DB, Armour JA, and Ardell JL. Chronic decentralization of the heart differentially remodels canine intrinsic cardiac neuron muscarinic receptors. Am J Physiol Heart Circ Physiol 281: H1919-H1930, 2001.
21. Stewart JA, Wei CC, Brower GL, Rynders PE, Hankes GH, Dillon AR, Lucchesi P, Janicki JS, and Dell'Italia LJ. Cardiac mast cell and chymase mediated matrix metalloproteinase activity and left ventricular remodeling in mitral regurgitation in the dog. J Mol Cell Cardiol 35: 311-319, 2003.
22. 1-adrenergic receptor blockade attenuates angiotensin II-mediated catecholamine release into the cardiac interstitium in mitral regurgitation. Circulation 108: 225-230, 2003.
23. Tsutsui H, Spinale FG, Nagatsu M, Schmid PG, Ishihara K, DeFreyte G, Cooper G, and Carabello BA. Effects of chronic β-adrenergic blockade on the left ventricular and cardiocyte abnormalities of chronic canine mitral regurgitation. J Clin Invest 93: 2639-2648, 1994.
24. Wainwright CL. Matrix metalloproteinases, oxidative stress and the acute response to acute myocardial ischaemia and reperfusion. Curr Opin Pharmacol 4: 132-138, 2004.
25. 2-Adrenoreceptor subtypes in canine intrathoracic efferent sympathetic nervous system regulating the heart. Am J Physiol Regul Integr Comp Physiol 261: R1269-R1275, 1991.